203 related articles for article (PubMed ID: 23561474)
1. 17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.
Schnaiter A; Stilgenbauer S
Hematol Oncol Clin North Am; 2013 Apr; 27(2):289-301. PubMed ID: 23561474
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Montserrat E; Dreger P
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2013 Sep; 88(9):803-16. PubMed ID: 23720127
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
6. An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease--case report.
Salihoglu A; Ozbalak M; Keskin D; Tecimer T; Soysal T; Ferhanoglu B
Transplant Proc; 2013 Sep; 45(7):2845-8. PubMed ID: 23747187
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
8. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
9. Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia
Davids MS; Kim HT; Yu L; De Maeyer G; McDonough M; Vartanov AR; Langey R; Fernandes SM; Hellman JM; Francoeur K; Arnason J; Jacobsen ED; LaCasce AS; Fisher DC; Brown JR
Leuk Lymphoma; 2019 May; 60(5):1312-1315. PubMed ID: 30322319
[TBL] [Abstract][Full Text] [Related]
10. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
Richardson SE; Khan I; Rawstron A; Sudak J; Edwards N; Verfuerth S; Fielding AK; Goldstone A; Kottaridis P; Morris E; Benjamin R; Peggs KS; Thomson KJ; Vandenberghe E; Mackinnon S; Chakraverty R
Br J Haematol; 2013 Mar; 160(5):640-8. PubMed ID: 23293871
[TBL] [Abstract][Full Text] [Related]
11. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
Tam CS; Stilgenbauer S
Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
[TBL] [Abstract][Full Text] [Related]
12. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
13. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.
Visco C; Finotto S; Pomponi F; Sartori R; Laveder F; Trentin L; Paolini R; Di Bona E; Ruggeri M; Rodeghiero F
Am J Hematol; 2013 Apr; 88(4):289-93. PubMed ID: 23450436
[TBL] [Abstract][Full Text] [Related]
14. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
Robak T; Blonski JZ; Wawrzyniak E; Gora-Tybor J; Palacz A; Dmoszynska A; Konopka L; Warzocha K; Jamroziak K
Cancer; 2009 Jan; 115(1):94-100. PubMed ID: 19025975
[TBL] [Abstract][Full Text] [Related]
15. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
[TBL] [Abstract][Full Text] [Related]
16. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.
Bagacean C; Tempescul A; Ternant D; Banet A; Douet-Guilbert N; Bordron A; Bendaoud B; Saad H; Zdrenghea M; Berthou C; Paintaud G; Renaudineau Y
J Immunother Cancer; 2019 Jan; 7(1):22. PubMed ID: 30696487
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
18. What do we do with chronic lymphocytic leukemia with 17p deletion?
Sellner L; Denzinger S; Dietrich S; Glimm H; Merkel O; Dreger P; Zenz T
Curr Hematol Malig Rep; 2013 Mar; 8(1):81-90. PubMed ID: 23188619
[TBL] [Abstract][Full Text] [Related]
19. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
20. Prognostic markers and standard management of chronic lymphocytic leukemia.
Stilgenbauer S
Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]